Home > Insider Trading > Filing (0001062993-23-019470)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1805387	Cerevel Therapeutics Holdings Inc.	CERE	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1164426	Joseph Edelman	51 Astor Place, 10Th Floor New York NY 10003	Yes	No	No	No
1224962	Perceptive Advisors Llc	51 Astor Place, 10Th Floor New York NY 10003	Yes	No	No	No
1249675	Ltd Fund Master Sciences Life Perceptive	51 Astor Place, 10Th Floor New York NY 10003	Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-10-16	876,808	$22.81	10,794,876	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	170,317	Indirect	See Footnote

Footnotes

Includes 3,406,341 shares of common stock the Master Fund (as defined below) received pursuant to a liquidation distribution by ARYA Sciences Holdings II on April 11, 2023 (the "Liquidation Distribution").
The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Mr. Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
Represents 170,317 shares of common stock received by Mr. Edelman on April 11, 2023 pursuant to a distribution by Perceptive SP(A), L.P. (the "Co-Investment Fund") which the Co-Investment Fund received pursuant to the Liquidation Distribution.
The securities are directly held by C2 Life Sciences, LLC ("C2"). The Advisor serves as the investment manager of C2 and Mr. Edelman is the managing member of the Advisor.